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Summary: Twenty patients with porphyria cutanea tarda who had ingested no alcohol for at least 10 days
before sampling were found to possess urinary Z>-glucaric acid levels similar to those of 30 clinically healthy
controls. Correlation between urinary excretion of D-glucaric acid on the one band and plasma or urinary
porphyrin concentrations on the other was not statistically significant. These results suggest that the high
urinary concentrations of Z>-glucaric acid found in porphyria cutanea tarda patients by Budillon et al. (Acta
Hepato-Gastroenterol. 25 (1978) 267) may have been due to recpnt consumption of alcohol rather than to
the porphyrin pathology.
Introduction
Porphyria cutanea tarda is due to hypoactivity of
hepatic uroporphyrinogen decarboxylase. Two types
have been described, sporadic and familial porphyria
cutanea tarda (l, 2). In the latter, erythrocyte uro-
porphyrinogen decarboxylase is also hypoactive. The
low enzyme activity results in supranormal hepatic
accumulation and urinary excretion of porphyrins,
particularly the most carboxylated species (uro and
heptacarboxyl pörphyrins).
The determination of Z>-gliicaric acid is frequently
used to evaluate hepatic microsomal activity in man
(3, 4). Budillon et al. (5) have repörted increased
urinary excretion of D-glucaric aqid by porphyria
cutanea tarda patients, with a highly significant cor-
relation between urinary Z>^glucaric acid and total
urinary porphyrin concentrations, and they concluded
that in porphyria cutanea tarda there is a close rela-
tionship between micfosomal flihction and the por-
phyrin metabolic derangement. If correct, these find-
ings suggest that determination of urinary D-glucaric
aeid and other indicators of hepatic microsomal func-
tion cöuld be used for clinical nionitoring of porphyria
cutanea tarda patients, but äs far äs we know they
have never been verified. In order to check this pos-
sibility, we studied urinary excretion of D-glucaric
acid in porphyria cutanea tarda. Since most porphyria
cutanea tarda patients have history of high alcohol
consumption, which increases urinary excretion of /)-
glucaric acid (6, 7), we avoided interference from this
cause by studying patients who had abstained from
consuming alcohol for long enough to ensure that it
would not affect their urinary D-glucaric acid con-
centrations.
Materials and Methods
Twenty male porphyria cutanea tarda patients were studied.
Fourteen were undergoing treatment consisting in periodic
phlebotomy and abstinence from alcohol; four of these cases
exhibited clinical and biochemical remission. The remaining six
patients had not yet begun phlebotomy treatment, but had
abstained from consuming alcohol for at least 10 days before
samples were taken for the present study. In a subsidiary study,
urine samples were collected from 5 porphyria cutanea tarda
patients, whose alcohol consumption had continued at least
until 24 hours before sampling. None of the patients was
diagnosed äs having cirrhosis of the liver or renal dysfunction.
Thirty clinically healthy male non-drinkers taking no drugs
were used äs a control group.
Urine was collected over 24 hours, and />-glucaric acid and
porphyrin concentrations were determined and related to urine
creatinine concentration. Urinary Z)-glucaric acid was deter-
mined by the enzymatic method of Simmons et al. (8), and total
urinary pörphyrins by the spectrophotometric method of D'A-
lessandro-Gandolfo & Topi (9), using the figures published by
Jacobs (10) for the absorptivities of uro- and coproporphyrin
in 1.5 mol/1 HC1. Uro- and coproporphyrin fractions were
determined in accordaiice with Leahy & Brien (11). In view of
the significant quantities of porphyrinogens excreted by por-
phyria cutanea tarda patients (12), a portion of each sample
was brought to approximately pH 7.5 with sodium carbonate
J. Clin. Chem. Clin. Biochem. / Vol. 25,1987 / No. 12
856 Tlitor et al.: Urinary />-glucaric acid in porphyria cutanea tarda
and stored in the dark for 48 hours at 4-8 °C before analysis;
under these conditions the oxidative conversion of the por-
phyrinogens to the corresponding porphyrins is practically com-
plete (10), while the porphyrins themselves remain stable (13).
Urinary creatinine was determined kinetically in a Hitachi 737
analyser using Jqffe's reaction.
Total plasma porphyrin concentrations were determined spec-
trophotometrically s per D'Alessandro-Gandolfo & Topi (14),
again using the absorptivities reported by Jacobs (10). Given
the significant levels of plasma porphyrinogens in patients with
porphyria cutanea tarda (15), the method was slightly modified
to ensure the conversion of porphyrinogens to the correspond-
ing porphyrins. Samples were at all times protected from light,
and analytical procedures were carried out without direct Illu-
mination so s to avoid the photodegradation of plasma por-
phyrins (16). Serum γ-glutamyltransferase was determined at
37 °C in a CentrifiChem 600 analyser using y-gl tamyl-/?-ni-
troanilide s Substrate and reagents from Smith Kliiie Instru-
ments.
The statistical significance of differences between the porphyria
cutanea tarda and control groups was estimated using Wilcox-?
on's test. Correlations were estimated by Pearson's coefficient
after normalization of the distributions involved.
Results
Table l lists the results obtained for the controls and
porphyria cutanea tarda patients without recent in-
take of alcohol. There were no statistically significant
differences between the urinary Z>-glucaric acid con-
centrations of these groups, or between those of pa-
tients presenting an active pathology with high plasma
and urinary porphyrin concentrations and those of
patients exhibiting clinical and biochemical remission.
In the patients with porphyria cutanea tarda there
was no significant correlation between urinary excre-
tion of £>-glucaric acid on the one hand and either
total urinary porphyrins (r = 0.073), uroporphyrin
(r = 0.095), coproporphyrin (r = 0.080), total plasma
porphyrins (r = 0.092) or γ-glutamyltransferase
(r = 0.132) on the other. No significant correlation
was found between serum γ-glutamyltransferase and
plasma or urinary porphyrin concentrations. Urinary
excretion of total porphyrins by porphyria cutanea
tarda patients was closely correlated with their plasma
porphyrin concentrations (r = 0.966, p < 0.001).
In the group of 5 porphyria cutanea tarda patients
who had continued drinking, no significant correla-
tion was found between urinary excretion of total
porphyrins and £>-glucaric acid (f = 0.103). Their uri-
nary Z>-glucaric acid concentrations ranged from 2.26
to 9.05 mmol/mol creatinine, with a mean of 5.63
mmol/mol creatinine and a median of 6.22 mmol/mol
creatinine. The differences with respect to the control
and "abstinent" porphyria cutanea tarda groups are
statistically significant (p < 0.01), and in 3 of the 5
cases, urinary jD-glucaric acid excretion exceeded the
uppef reference limit. The urinary Z)^glucaric acid
concentration of a group of non-porphyria cutanea
tarda alcoholics, who had recently taken alcohol, was
likewise significantly higher (p < 0.001) than in the
control group (17).
Discussion
Bacon et al. (18) have recently found in vivo that
overloading the liver with iron induces microsomal
lipid peroxidation, with a decrease in cytochrome P-
450, cytochrome b5 and aminopyrine demethylase. It
is also well known that a large proportion of porphy-
ria cutanea tarda patients present hepatic siderosis (2,
19, 20, 21) of a severity ranging from slight to levels
similar to those found in idi pathic haemochroma-
tosis (2). Blekkenhorst et al. (22) nevertheless found
that porphyria cutanea tarda (though not other por-
phyrias) was associated with hepatic cytochrome P-
450 levels significantly higher than normal; though
paradoxically they were unable to detect the prolif-
eration of the smooth endoplasmic reticul m usually
observed during hepatic enzyme induction.
Tab. 1. /)-Glucaric acid, total porphyrin and γ-glutamyltransferase in controls and porphyria cuta&e tarda patients without
recent intake of alcohol.
Control group Porphyric group Significance
D-Glucaric acid
(mmol/mol creatinine)
Urinary porphyrins
(μιηοΐ/mol creatinine)
Plasma porphyrins
(nmol/1)
γ-Glutamyltransferase
(U/l)
N
30
30
—
30
Mean (Range)
1.95(0.98- 4.10)
11.37(2.62-18.58)
—
18.93(7-39)
Medi n
1.84
12.57
—
16.00
N
20
20
17
17
Mean (Range)
2.05 (0.98- 4.69)
337.71(10.25-819.84)
100.52(10.06-333.10)
63.18 (16 -220)
Median
1.96
265.80
46.94
42.00
p = 0.2
p < 0.001
—
p < 0.001
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In man, Z>-glucaric acid is the end product of hepatic
glucuronic acid metabolism. Its concentration in urine
is increased by the action of microsomal enzyme-
inducing compounds, and under these conditions uri-
nary D-glucaric acid concentrations are significantly
correlated with hepatic cytochrome P-450 (23,24,25).
As was mentioned above, Budillon et al. (5) reported
that in a study of nine porphyria cutanea tarda pa-
tients, most of them heavy alcohol consumers, they
found above-normal urinary excretion of /)-glucaric
acid and a highly significant correlation between uri-
nary D-glucaric acid concentrations and total urinary
porphyrin concentrations.
Most male porphyria cutanea tarda patients have a
history of heavy alcohol consumption, but it is un-
likely that alcohol or alcoholic hepatopathy by them-
selves can turn secondary coproporphyrinuria into
poφhyria cutanea tarda (21). Besides triggering
agents such s alcohol or oestrogens and the "per-
missive" role of iron, other aetiological factors must
necessarily be involved (2). Induction of hepatic mi-
crosomal function by alcohol alters the pharmacoki-
netics of antipyrine (26, 27) and raises the activity of
hepatic cytochrome P-450 (20, 26) and urinary D-
glucaric acid (6, 7,28). Be that s it may, once ethanol
consumption has ceased, the induction effect seems
to disappear in a short period of time; the half-life of
antipyrine in plasma returns to normal within two
weeks (27) and urinary Z)-glucaric acid concentrations
within eight days (7), the latter parameter falling most
sharply in the first three days of abstinence (17).
Clinical and bioehemical remission of poφhyria cu-
tanea tarda, on the other band, does not seem to be
brought about by abstinence alone (29), and it can
apparently be achieved by periodic phlebotomy eVen
when alcohol consumption continues (30), though
abstinence may play an important role in maintaining
remission (20).
None of the poφhyria cutanea tarda patients involved
in the first p rt of the present study had consumed
alcohol within the previous 10 days, so that alcohol
cpuld have had no effect on their urinary Z)-glucaric
acid concentrations. The abse ce of both urinary D-
glucaric acid levels greater thari those of the contf ols,
and the significant correlation between these levels
and plasma or urinary porphyrin c ncentrations
therefore suggests that the results of Budillon et al.
(5) may have been due, at least in paft, to recent
alcohol consumption rather than to the porphyrin
pathology. The present results lend no support to the
hypothesis that the alterations of porphyrin metabo-
lism in porphyria cutanea tarda are closely related to
hepatic microsomal function.
γ-Glutamyltransferase has been suggested s a useful
index of hepatic enzyme induction (4), and in alco-
holics with recent consumption of alcohol (17, 28)
and in male patients treated with antiepileptic drugs
(31) it is significantly correlated with urinary excretion
of D-glucaric acid. The high serum γ-glutamyltrans-
ferase activities frequently observed in porphyria cu-
tanea tarda cases (rarely in other hepatic porphynas)
are possibly due to the enzyme induction by alcohol
and/or to liver damage. The patients involved in the
present study exhibited no significant correlation be-
tween γ-glutamyltransferase activity and either uri-
nary excretion of £>-glucaric acid, or plasma or uri-
nary porphyrin concentrations.
cutanea tarda is almost always accom-
panied by some form of hepatopathy, though the
latter is usually clinically subdued and moderate s
regards its biochemistry, anatomopathology and pro-
gression (21). Although liver cirrhosis decreases the
urinary excretion of Z)-glucaric acid (32) and the
activity of hepatic cytochrome P-450 (33), above-
normal urinary £>-glucaric acid concentrations have
been found in association with different hepatopathies
(34), which may explain the increased levels in some
patients with porphyria cutanea tarda.
Sweeney (20) has suggested that the ability of certain
halogenated aromatic hydrocarbons to cause ροφΐ^-
ria in laboratory animals might be due in part to their
induction of hepatic microsomal cytochromes, though
in porphyrinogenesis iron is likewise clearly involved.
The relationship between cytochrome induction and
the role of iron in causing uroporphyrinogen decar-
boxylase deficiency is unknown (20). The urinary D-
gl caric acid results of the present study do not sup-
port the hypothesis that in porphyria cutanea tarda
the ροφΙ^Γΐη metabolic derangement is correlated
with hepatic microsomal function. However, since D-
glucaric acid excretion represents an indirect para-
meter of microsomal enzyme induction, other tests
such s 6 -hydroxycortisol which is formed via he-
patic cytochrome P-450 might afford helpful data.
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